Jim Cramer’s claim of no Eli Lilly sell‑off fuels market speculation
Executive summary: Jim Cramer denied selling Eli Lilly stock, responding to speculation about a possible disposal. The remark influences investor sentiment toward Eli Lilly and underscores how media commentary can affect market perception of pharma stocks. Jim Cramer, Eli Lilly, investors, financial media outlets. Further analyst commentary, possible clarification from Cramer, and monitoring of Eli Lilly's stock price in the coming days.
On June 13, 2026, CNBC analyst Jim Cramer said he was not selling shares of Eli Lilly (LLY), addressing market speculation about a potential disposal. He made the comment during a video where he responded to rumors circulating on social platforms. No concrete evidence of a sale was presented, and the statement comes amid broader volatility in pharma stocks. The market showed only modest trading volume changes in LLY, with no definitive price movement observed.
Connected developments
- If You Have $10,000 And Want To Bet on AI and Robotics, These Are The Investments I’d Pick
- Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.
- Prediction: Eli Lilly Will Trade at This Price in a Year
Open the full case file on Beyond →
Social Pulse
AI estimate · not scraped